Euan joined the Genea Board in March 2009 as a non-executive director and is Chairman of the Science and Research Commercialisation Committee.
Specialising in structured finance, commercialisation and funding of R&D programs for the biotechnology industry, Euan will be overseeing the capital raising requirements and establishment of Genea Biocells as an independent business.
Euan has more than 20 years’ experience as a practising CPA and Chartered Accountant including 10 years as a partner of PwC. He is a former director, chief financial officer and company secretary of Vision Systems Ltd and a former director of AFL Films and Invetech Ltd.
Dr. Schmidt has over 15 years of R&D and technology commercialization experience in cell biology, stem cells, drug discovery and screening. He co-authored over 20 peer-reviewed scientific publications and is an inventor of 10 patent/application families. Dr Schmidt is now an executive of Genea Limited and as General Manager of Genea Biocells shapes the company’s scientific direction and business strategy. Prior to joining Genea in 2007, he founded a company for novel GPCR drug screening technologies and was the scientific founder of a European diagnostics/drug delivery company.
Dr. Stojanov has over 26 years of experience in diverse aspects of the health, biotechnology and agriculture sectors from the perspective of scientific research, operational management and technology commercialization.
Dr. Arjomand has over 15 years of pharmaceutical and biotechnology experience and co-authored 15 scientific publications. He joined Genea Biocells in 2013 and helped coordinate Genea Biocells’ opening of their new R&D facility in San Diego, CA. He currently manages the scientific direction and collaborative efforts necessary to expand Genea Biocells’ drug discovery efforts and revenue streams. Previously, Dr. Arjomand was the Director of Basic Research at High Q Foundation/CHDI Management (USA) a not-for-profit foundation dedicated to Huntington’s disease (HD) therapeutics. He designed and managed a complex portfolio comprising of academic, clinical and industry driven projects in support of Foundation drug discovery efforts.
Dr. Kiselyov has over 20 years of Pharma/Biotech and Foundation experience in drug discovery and preclinical development. He oversees all chemistry aspects of Genea Biocells’ drug discovery program as well as chemical genomics, biophysics, structural biology, target ID/validation and systems biology relevant to pluripotency, differentiation and proliferation of stem cells. Previously, Dr Kiselyov has authored and directly contributed to over 10 clinical programs across multiple therapeutic areas including oncology (Motesanib™ for the treatment of renal carcinoma, Phase III), cardiovascular disease (Veliflapon™ for the treatment of acute CV events associated with coronary arthery disease, Phase III; DG041 and DG051 for the treatment of artherial thrombosis and atherosclerosis, respectively, Phase IIb); dementias and cognitive disorders (DG071, Phase Ib); Spinal Muscular Atrophy (SMA, RG3039 Phase Ib) and others.
Dr. Bennett joined the Genea Biocells team on July 11, 2016 as Director of Preclinical Research. Dr. Bennett has over 10 years of translational research experience in the areas of stem cell biology, neuroscience, and muscle biology. Her biotechnology experience includes developing both protein and cellular therapeutics in degenerative diseases of skeletal muscle at Fate Therapeutics and leading research activities in the areas of neuroscience, metabolic and cardiovascular biology at Orexigen Therapeutics. Dr. Bennett received her Ph.D. from Stanford University with a focus on developmental neurobiology and completed her postdoctoral training at the Harvard Stem Cell Institute where she investigated the neurodegenerative condition Spinal Muscular Atrophy.
Dr. Colman has over 40 years of R&D experience in both academic and industry laboratories. His illustrious career as a scientist started by training under Nobel laureate Prof John Gurdon. His early work focused on human protein secretion from frog eggs and in the milk of transgenic animals and culminated with his involvement in making the Dolly the Sheep in 1996. With the emergence of human pluripotent stem cell technologies, Dr Colman focused on differentiation, disease modeling and regenerative medicine. Dr Colman has co-authored over 150 scientific publications.
Dr. Loring is a prominent stem cell scientist whose laboratory focuses on the genomics and epigenetics of human pluripotent stem cells. Her research group is developing stem cell-based therapies for Parkinson’s disease, multiple sclerosis, and Fragile X syndrome/autism. The group is also working with the San Diego Zoo to generate stem cells from endangered species, in an effort to rescue animals from the brink of extinction. Dr Loring is also recognized for her public involvement in bioethics, stem cell patenting, and regulation of stem cell therapies (“stem cell tourism”).
Prof. Metzger has more than 15 years of experience in pharmaceutical R&D with a proven track record of translation into the clinic. He has a strong scientific expertise on therapeutic approaches in neurological and rare neuromuscular diseases, and he is the author and inventor of over 60 publications and patents. Currently, Prof. Metzger is the Chief Executive Officer and co-founder of Versameb, a regenerative medicine R&D company, and Professor of Neurobiology at the University of Freiburg, Germany. He was previously the Head of Discovery, Rare Diseases at Roche in Basel, Switzerland where he initiated multiple drug discovery programs and led them into the clinic, among them Risdiplam which is currently in pivotal trials in SMA. He participated in many due diligence processes and was part of the team that launched stem cell research at Roche.